Feb. 7, 2005 -- The European Commission has approved an expanded indication for peginterferon alfa-2a injection, allowing its use in the European Union for the treatment of hepatitis C virus in ...

Co reported on the presentation of results from clinical trials of Velcade based therapies that showed high complete remission / complete response rates in previously treated multiple myeloma patients ...

WASHINGTON -- The government has approved a novel cancer treatment for one of the hardest-to-treat malignancies, rushing the drug Velcade to multiple myeloma patients in hopes it will buy them some ...

Co reported on the presentation of results from four clinical trials of Velcade based therapies that showed consistently high survival and complete remission / complete response rates in newly ...

April 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved mometasone furoate inhalation powder for the maintenance treatment of asthma as prophylactic therapy in patients aged 12 ...

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. The Food and Drug Administration (FDA) has approved ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa ...

Amneal and Shilpa have received the Food and Drug Administration’s permission for Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration.

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces the ...